Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 7/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LPL | P06858 | 2/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16293433 | 0.82 | ENPP2 (0.48) | TRPA1MGLLENPP2CA4CA6 | |
| SCHEMBL3787098 | 0.82 | HDAC4 (0.53) | MGLLENPP2CA4CA6CA5A | |
| SCHEMBL16293432 | 0.82 | ENPP2 (0.48) | TRPA1MGLLENPP2CA4CA6 | |
| SCHEMBL2722929 | 0.80 | FFAR1 (0.46) | MGLLENPP2KDM4EALDH1A1LPL | |
| SCHEMBL129343 | 0.77 | ENPP2 (0.50) | MGLLENPP2CA4CA6CA5A | |
| SCHEMBL31430960 | 0.77 | ENPP2 (0.50) | MGLLENPP2CA4CA6CA5A | |
| SCHEMBL3672929 | 0.77 | TRPA1 (0.67) | TRPA1TAAR1KDM4EALDH1A1AOC3 | |
| SCHEMBL1812495 | 0.76 | ENPP2 (0.48) | MGLLENPP2CA4CA6CA5A | |
| SCHEMBL2440765 | 0.74 | PTGS1 (0.56) | MGLLKDM4EALDH1A1 | |
| SCHEMBL5096934 | 0.74 | ENPP2 (0.50) | MGLLENPP2CA4CA6CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759729-B2 | Compounds for treating diabetes | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2020-09-01 | — | — | US | disclosed |
| US-20180127343-A1 | NOVEL COMPOUNDS FOR TREATING DIABETES | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759729-B2 | Compounds for treating diabetes | SLC5A2, GPR119, DPP4 | TRPA1 4364/4885MGLL 363/4885ENPP2 352/4885 |
| US-20180127343-A1 | NOVEL COMPOUNDS FOR TREATING DIABETES | GPR119, SLC5A2, DPP4 | TRPA1 4655/4885MGLL 307/4885ENPP2 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.